Specific binding of human growth hormone but not insulin-like growth factors by human adipocytes  by DiGirolamo, Mario et al.
Volume 205, number 1 FEBS 3942 September 1986 
Specific binding of human growth hormone but not 
insulin-like growth factors by human adipocytes 
Mario DiGirolamo, Staffan Eden+, G&a Enberg”, Olle Isaksson+, Peter Lonnroth, Kerstin Hall” 
and Ulf Smith* 
Departments qf Medicine II and +Physiology, University of Gothenburg, Gothenburg and “Department of Endocrinology, 
Karolinska Institute, Stockholm, Sweden 
Received 16 May 1986 
Binding of human GH (hGH) and insulin-like growth factors I and II (IGFI and II) to isolated human 
adipocytes from adult subjects was studied. Binding equilibrium for hGH at 24°C was reached at 120 min 
and half-maximal specific binding at 6-8 ng/ml. Apparent K, was 2.1 x log M-l and B,,, 7.3 x 10 -ii 
M/lo6 cells. The human fat cell growth hormone receptor recognized neither bovine, ovine or rat GH nor 
human prolactin or placental lactogen. No specific receptors for human IGFII could be demonstrated. 
Thus, human adipocytes do not possess IGF receptors but have specific GH receptors which recognize hGH 
but not GH from lower species. 
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1. INTRODUCTION 
The human organism is exclusively responsive to 
primate growth hormone (GH) whereas lower 
species respond to GH from human and many 
other animal sources [I]. An explanation for these 
findings is not readily available. 
Isolated adipocytes or adipose tissue fragments 
from several species, including rat and human, re- 
spond to growth hormone stimulation [2-71. We 
have also recently shown that isolated fat cells 
from normal rats possess pecific binding sites for 
hGH [6,7]. In these studies, GH from species other 
than the human were recognized by the rat adipo- 
cyte GH receptors to variable degrees. Several 
previous studies have shown that rat fat cells also 
possess specific receptors for the insulin-like 
growth factors (IGF) [8], particularly IGFII [9]. 
The metabolic insulin-like effect of these growth 
factors seems to be mediated by their ability to 
bind to the insulin receptors [8]. However, a more 
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complicated interaction between insulin and IGF is 
also evident as insulin increases IGFII binding in 
rat adipocytes by translocating receptors from an 
intracellular pool to the plasma membrane through 
an energy-requiring process very similar to the ef- 
fect of insulin on glucose transport units [9]. 
The aim of the present study was to investigate 
whether human fat cells possess specific receptors 
for these growth factors. 
2. MATERIALS AND METHODS 
2.1. Tissue sources 
Biopsies of abdominal subcutaneous adipose 
tissue were obtained from 20 subjects, 34-75 years 
of age and with a relative body weight of 
83-l 70%) undergoing elective surgery. 
2.2. Hormone binding 
Isolated fat cells were prepared by incubating 
small fragments with collagenase as described [IO]. 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/86/$3.50 0 1986 Federation of European Biochemical Societies 15 
Volume 205, number 1 FEBS LETTERS September 1986 
The isolated cells (- 3 x lo5 cells/l 5 ml) were in- 
cubated with ‘251-labelled insulin, hGH, hIGF1 or 
hIGFI1 in the presence of variable concentrations 
of unlabelled hormone (2-5000 ng/ml) in medium 
199 containing 4% albumin for 2 h unless other- 
wise specified. 
In the experiments aimed at elucidating receptor 
specificity, 3000 ng/ml of either hGH, rGH, bGH 
were added to the vial containing 4.4 ng/ml “‘I- 
hGH. Similarly, human thyroid stimulating hor- 
mone (hTSH), human adrenocorticotropic hor- 
mone (hACTH), human prolactin (hPRL) and 
human placental actogenic hormone (hPRL) were 
tested for the degree of competition at concentra- 
tions of 500-5000 ng/ml. 
At the end of the incubation period, samples of 
the cell suspension were centrifuged in microtubes 
through dinonyl phthalate as described by 
Gliemann et al. [l 11. Total number of fat cells in 
each vial was calculated by dividing the triglyceride 
content by the mean cellular lipid weight as 
described [lo]. Non-specific binding, estimated 
from the non-saturable binding [12], was sub- 
tracted. Specific hGH binding was expressed on a 
per cell basis after correcting for non-specific 
binding. Hormone degradation during the binding 
assay was monitored by measuring the pre- 
cipitability of label with 10% trichloroacetic acid. 
The degradation was less than 15%. 
2.3. Glucose transport 
In some experiments glucose transport was 
measured essentially as described by Kashiwagi et 
al. [13]. Briefly, cells at a lipocrit of 3-5% were 
preincubated at 37°C with or without the addition 
of hormone in a glucose-free medium. After 15 
min, [U-14C]glucose was added at a final concen- 
tration of 50 nM (- 0.2 &i/tube). After 60 min, 
cells and medium were separated through dinonyl 
phthalate [ 1 l] and the uptake determined. Control 
experiments were also performed with 3-0- 
[‘4C]methylglucose uptake using described incuba- 
tion conditions [ 141. 
2.4. Hormones 
Purified hGH, with an estimated potency of 2 
U/mg was kindly supplied by Kabi AB, 
Stockholm, Sweden. Human IGFI and IGFII were 
purified as described [ 151. hACTH was provided 
by Kabi AB, Stockholm, Sweden, bGH (NIH- 
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bovine GH-18), oGH (NIH-ovine GH-5-6) and 
rGH (NIH-rat GH-B-6) were provided by the 
Pituitary Agency of the National Institutes of 
Health. 
Human IGFI and II were iodinated according to 
published procedures [ 151. Purified hGH was 
iodinated with Nai2? as described by Thorell and 
Johansson [ 161. 1251-insulin was kindly supplied by 
Dr Sten Ivarsson, Malmo. 
3. RESULTS 
3.1. hGH binding 
Initial experiments of the time-course for “‘I- 
hGH binding at 24°C showed that equilibrium had 
been established by 2 h and persisted throughout 3 
h. All subsequent binding experiments were, 
therefore, carried out for 2 h. 
Addition of unlabelled hGH completed in a 
dose-related manner with “‘1-hGH binding. 
Specific binding per lo6 fat cells reached saturation 
at hGH concentrations of 50 ng/ml (fig.1). Half- 
maximal binding was observed at 6-8 ng/ml of 
unlabelled hormone. Non-specific binding aver- 
aged 38+6% (mean+SE, n = 11). 
A Scatchard plot of the data presented in fig.1 
(inset) revealed a single class of binding sites with 
an apparent Ka of 2.1 x lo9 M-’ and an estimated 
B max of 7.3OO/cell. 
Fig. 1. Specific binding of hGH to human fat cells after 
2 h incubation at 24°C. The data represent the mean f 
SE of triplicate samples from 11 subjects. The incuba- 
tion flasks contained “-?-hGH without or with increas- 
ing amounts of unlabelled hGH to achieve final hor- 
mone concentrations of 6-140 ng/ml. Inset shows the 
Scatchard plot of the same data. 
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Table 1 shows the ability of different peptide 
hormones to displace labelled hGH from adipocyte 
hGH receptors. It is clear from the lack of inhibi- 
tion shown by rGH, bGH and oGH that the 
human adipocyte GH receptor failed to recognize 
GH from the other species tested. Furthermore, no 
significant inhibition of ‘*‘I-hGH binding was 
found with hPRL or hPLH (table 1) or with other 
peptide hormones like hACTH, hTSH, or human 
IGFII (not shown). 
Table 2 
Binding of human ‘251-IGFII to human fat cells 
Additions to medium Unlabelled IGFII, ng/ml 
0 10 50 100 loo0 
None loo 100 104 98 97 
+2-t4*3 lt2 
Insulin (42 ng/ml) 102 102 105 97 93 
+5+5*3 +4 rt2 
3.2. IGF binding 
No consistent specific binding of either human 
‘*‘I-1GFI or IGFII was found in fat cells from 9 
adult individuals tested. Non-specific binding 
averaged 85 + 15% of total binding. The lack of 
specific IGF binding sites in human fat cells was in- 
dependent of temperature (24 or 37”C), incubation 
time (up to 3 h), addition of 1 mM KCN to prevent 
recycling of the IGFII receptors [9] or preincuba- 
tion with a high insulin concentration (table 2). 
Isolated fat cells from 5 adult individuals were prein- 
cubated for 60 min at 37°C with 42 ng/ml insulin. After 
55 min, 1 mM KCN was added to prevent recycling and 
5 min later 0.3 ng/ml ‘251-IGFII was added and the vials 
were incubated at 24°C for an additional 60 min. All 
results (mean + SE) are expressed relative to total 
binding obtained in the absence of unlabelled IGFII (= 
100%) 
In spite of the absence of specific binding sites, 
human IGFII stimulated both [U-14C]glucose up- 
take (table 3) and 3-O-[14C]methylglucose uptake 
(not shown) but exceedingly high concentrations 
were required (- lo&fold higher than for insulin) 
suggesting that this effect may be mediated 
through the insulin receptors. This is supported by 
Table 1 
Inhibition of ‘*?-hGH binding by GH from human or 
non-human species 
Peptide hormones % inhibition of specific 
(3 &ml) ‘251-hGH binding 
hGH 100 
rGH 1*2 
bGH -6 & 7 
oGH -1 * 6 
hPRL -4 
hPLH -6 
GH preparations from different species were incubated 
at 3000 ng/ml in the presence of 7.4 ng/ml ‘251-hGH for 
2 h at 24°C. Each value represents the mean f SE of 
triplicate determinations in 3 experiments. The results 
with human prolactin (hPRL) and placental lactogenic 
hormone (hPLH) are the means of one experiment per- 
formed in triplicates. Values shown indicate degree of 
inhibition of binding relative to that seen with unlabelled 
Table 3 
The effect of insulin and human IGFII on ‘251-insulin 
binding and glucose transport in human fat cells 
Additions to Glucose “‘I-insulin 
medium ng/ml clearance binding 
(M) (fl/cell per s) (‘70 of control) 
None 1.5 100 
IGFII 0.8 (IO-“) 1.4 98 
8 (lo-‘) 1.4 97 
80 (lo-8) 2.3 87 
Insulin 0.6 (lo-“) 2.3 85 
6 (lo-‘) 2.8 39 
60 (lo-*) 2.5 8 
Isolated human fat cells were incubated with 
[U-‘4C]glucose or “‘I-insulin for 60 min and with 
unlabelled hormone as indicated. The results are the 
means of duplicate determinations of a representative 
experiment 
the finding that IGFII at these concentrations com- 
peted with the binding of “‘I-insulin to the insulin 
receptor (table 3). 
4. DISCUSSION 
hGH (= 100%) The present study demonstrates that human 
17 
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adipocytes contain specific hGH receptors but, 
surprisingly, no receptors for the insulin-like 
growth factors I and II could be demonstrated. 
The half-maximal specific binding of hGH was 
reached at physiological hormone concentrations, 
indicating that these specific binding sites may in- 
deed be functional receptors for the hormone. 
Human adipocytes, like rat adipocytes, are target 
cells for GH [2-71. However, only the insulin- 
antagonistic effect of hGH has been demonstrated 
in human fat cells [5] while rat fat cells respond 
with both an initial insulin-like and a subsequent 
insulin-antagonistic effect [6,7]. 
It is not surprising that a hormone which pro- 
duces biological effects is also specifically 
recognized and bound by the target cell. The 
binding kinetics for hGh to human fat cells are 
very similar to recent findings with human blood 
cells [17] but are both quantitatively and quali- 
tatively different from those of rat adipocytes. The 
total number of binding sites appears to be lower 
in human than in rat fat cells [6]. The most signifi- 
cant difference, however, is the inability of growth 
hormone from non-primate species to interact with 
the hGH receptor sites on human fat cells. This is 
in clear contrast to the rat adipocytes which have 
been shown to recognize growth hormone from 
several species [6]. The lack of recognition by the 
human cells of other species of growth hormone is 
consonant with the known species differences in 
the biological action of growth hormone and may 
indeed be responsible for them. 
The lack of specific binding sites for both IGFI 
and II in human fat cells is also in marked contrast 
to the findings with rat adipocytes where binding 
of both IGFI and II to the IGFII receptors has 
repeatedly been demonstrated [9]. Furthermore, in 
rat fat cells insulin markedly increases IGFII 
binding through the translocation of receptors 
from a large intracellular pool to the plasma mem- 
brane, similar to the effect of insulin on the 
glucose transporters [9]. However, in the human 
adipocytes no such effect of insulin could be 
demonstrated. The complete absence of both IGFI 
and II receptors excludes an important role of 
these growth factors in the metabolic effect of in- 
sulin in the mature human fat cell. It is interesting 
to note that human fibroblasts differ in this respect 
as specific binding of IGFII has clearly been 
demonstrated in these cells [18]. It is not clear 
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Table 4 
Comparison of rat and human adipocyte membrane 
binding of growth factors 
Rat cells Human 
Specific binding of hGH + + 
Recognition of non-primate GH 
by hGH receptor + - 
Specific binding of insulin + + 
Specific binding of IGFII + _ 
Effect of insulin in enhancing 
IGFII binding + - 
whether this difference mirrors the different cells 
or the degree of maturation of the cells. 
The insulin-like effect of IGFII was 
demonstrated in human fat cells but the potency 
was around two orders of magnitude less than for 
insulin. Since IGFII has a low affinity for the in- 
sulin receptor in human fat cells (table 3) it is likely 
that this stimulatory effect is also mediated 
through the insulin receptors, analogous to 
findings with rat fat cells [8,18]. 
In conclusion, the demonstration of specific 
hGH binding sites in isolated human adipocytes 
may be useful for the exploration of the relation- 
ship between cellular binding, plasma levels and 
biological effects of this hormone during growth 6 
and development and in abnormal states such as 
short stature and acromegaly. Additionally, this 
may prove to be a useful system to evaluate struc- 
ture, activity and binding characteristics of dif- 
ferent GH preparations and fragments. 
The salient differences between binding and ac- 
tion of GH and IGF in rat and human fat are sum- 
marized in table 4. 
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